Galectin Therapeutics (GALT) Stock Climbs On Data Publication

Galectin Therapeutics GALT Stock News

Galectin Therapeutics Inc. (NASDAQ: GALT) is screaming for the top in the market this morning, squeezing the shorts out of their positions after announcing a paper published in a peer-reviewed Journal surrounding belapectin. Here’s what’s going on: GALT Announces Data Publication In the press release, Galectin therapeutics announced that data from a study of its … Read more

Galectin Therapeutics (GALT) Stock: Climbing On Clinical Data

Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company released positive preliminary clinical data from a Phase 1b clinical trial of GR-MD-02. Of course, the data excited investors who are sending the stock on a run for the top. … Read more

Galectin Therapeutics (GALT) Stock: Flying On Patent News

Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) is having a great start to the trading session this morning after the company announced that it has received a new patent. Of course, the additional protection of intellectual property excited investors, sending the stock screaming for the top. Today, we’ll talk about: The patent; what we’re seeing … Read more

Galectin Therapeutics (GALT) Stock: Gaining On Positive Clinical Data

Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) Galectin Therapeutics is having an incredibly strong day in the pre-market hours this morning. The gains come following the company’s announcement of positive clinical data. Below, we’ll talk about what we’re seeing from GALT, why the stock is headed upward, and what we’ll be watching for ahead. What … Read more

Galectin Therapeutics (GALT) Stock: Here’s Why It’s Up!

Galectin Therapeutics Inc. Common Stock (NASDAQ: GALT) Galectin Therapeutics is having an incredible time in the market at the moment, and for good reason. The company is making serious headway with GR-MD-O2. On top of that, a recent acquisition between Allergan plc (NYSE: AGN) and Tobira Therapeutics (NASDAQ: TBRA) is leading to further excitement surrounding … Read more